US-Iran Ceasefire Offers Brief Stability for Global Pharma Supply Chains

The global pharmaceutical supply chain was granted a 14-day reprieve on April 7, 2026, after the US and Iran agreed to a Pakistani-mediated ceasefire just hours before a critical military deadline.¹ The agreement marks a significant de-escalation in the immediate conflict, and trade ships are expected to resume passage through the Strait of Hormuz during the two-week interval.²

Despite the ceasefire update, uncertainty remains around exact details of the agreement and its relation to trade passage. After news of the ceasefire broke, President Donald Trump suggested securing the Strait in a “joint venture” with Iran, while Iran said it will coordinate the passage of ships with its military.¹ Some shipping experts also cautioned against anticipating a speedy return to normal trade in the passage.¹

Why is Securing the Strait Critical for the Global Pharma Supply Chain?

The Strait of Hormuz is a critical maritime trade corridor, primarily for the global petroleum trade. In an email exchange with Pharmaceutical Executive, the United States Pharmacopeia (USP) noted, “The Strait of Hormuz is less likely to disrupt pharmaceutical shipments directly, but it remains a critical route for global petroleum transport.”USP continued, “Petroleum-derived inputs are essential to the production of key starting materials, so rising energy prices could further compress margins. Pricing pressure is already recognized as a major strategic driver of pharmaceutical supply chain risk.”³

An estimated 30,000 vessels pass through the strait each year, carrying about a fifth of the world’s seaborne oil and natural gas, as well as aluminum, helium, and chemicals used in pharmaceutical production.⁴

How Has the US-Iran Conflict Affect Air Transport?

Air transportation also felt the effects of the conflict. As the closure and reduced operation of major Gulf air hubs has further constrained the movement of high-value, time-sensitive medical goods.

Air freight plays an essential role in transporting biologics, specialty medicines, and temperature-sensitive products. Disruptions in these hubs can cascade quickly, creating bottlenecks that extend far beyond the region. Major Gulf air hubs in the Gulf Cooperation Council (GCC) region includes locations in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE). These serve as critical pharmaceutical transit hubs connecting Africa, Asia, Europe, India, and the United States.⁴

The GCC's growing pharmaceutical industry is worth $23.7 billion, around 80% of which relies on imports through the GCC airspace and the Strait of Hormuz.⁵

How Has the Conflict Affect the Global Pharma Industry So Far?

The most immediate effects of the U.S.-Iran conflict are being felt in the supply of active pharmaceutical ingredients (APIs) and other upstream materials. Many pharmaceutical firms depend on globally dispersed manufacturing networks, with raw materials often crossing several borders before reaching final production.³

Delays in shipping and extended transit times are disrupting production timelines, particularly for generic-drug manufacturers that operate with tighter margins and minimal inventory buffers. The pressure extends beyond APIs to the entire supply chain, including excipients, packaging materials, and the distribution of finished products. Some shipments are reportedly being postponed or rerouted, which increases costs and complicates inventory planning.³

According to USP, direct manufacturing in the region remains limited, accounting for roughly 0.3% of API production and 0.6% of oral solid dose production, with the bulk of activity concentrated in Israel and Jordan.³

In a USP document shared with Pharmaceutical Executive, the organization highlights certain products that have significant regional dependence despite the small overall manufacturing footprint, including:

• 48% of amoxicillin oral suspension produced in Jordan
• 24% of doxycycline hyclate capsules produced in Jordan
• 73% of flumazenil API produced in Israel and Jordan
• 48% of etomidate API produced in Jordan

What Happens Next?

The current ceasefire provides a helpful pause for the pharmaceutical industry, but the situation remains delicate. While trade through the Strait may resume for now, this period highlights the complex link between regional stability and the steady flow of medical supplies. Navigating these supply chain challenges will likely require continued diplomatic efforts and careful planning as the industry watches for a more permanent resolution.

References

1. CNN. Iran war live updates: Trump, US, Iran ceasefire. Published April 8, 2026. Accessed April 8, 2026. https://www.cnn.com/2026/04/08/world/live-news/iran-war-trump-us-ceasefire
2. Breuninger K. Trump says Iran ceasefire tied to Strait of Hormuz reopening. CNBC. Published April 7, 2026. Accessed April 8, 2026. https://www.cnbc.com/2026/04/07/trump-iran-ceasefire-hormuz-strait.html
3. Jacobus N. Medical supply chains at risk over escalating conflicts in Iran: report. Pharmaceutical Executive. Published 2026. Accessed April 8, 2026. https://www.pharmexec.com/view/medical-supply-chains-risk-over-escalating-conflicts-iran-report
4. Al-Hashemi M. The Strait of Hormuz is not just an oil chokepoint. Al Jazeera. March 27, 2026. Accessed April 8, 2026. https://www.aljazeera.com/opinions/2026/3/27/the-strait-of-hormuz-is-not-just-an-oil-chokepoint
5. Where the Iran war could disrupt pharmaceutical supply chains. Think Global Health. March 20, 2026. Accessed April 8, 2026. https://www.thinkglobalhealth.org/article/where-the-iran-war-could-disrupt-pharmaceutical-supply-chains